Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response - 01/09/11
, W.F. Eddie Lau b, c, Monica A. Slavin a, d
Corresponding author. Department of Microbiology and Infectious Diseases, Sydney South West Pathology Service, Locked Bag 7090, Liverpool BC, NSW 1871, Australia. Tel.: +61298285163; fax: +61298285129.Summary |
Active tuberculosis (TB) infection including asymptomatic and extrapulmonary disease may be detected with 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). This report highlights the promising role of FDG-PET/CT for evaluation of TB in high-risk, immunocompromised patients with cancer. PET/CT performed for cancer evaluation may detect asymptomatic infection and guide definitive diagnosis. It may also be a useful tool in the assessment of latent TB, to exclude active disease prior to treatment. PET/CT has potential for monitoring response to anti-tuberculosis treatment. Metabolic response may indicate clinical response and guide duration of anti-microbial therapy.
Le texte complet de cet article est disponible en PDF.KEYWORDS : Tuberculosis, Treatment, Malignancy, Positron emission tomography, Interferon-gamma
Vol 87 - N° 5
P. 459-463 - septembre 2007 Retour au numéro
Article précédent
- Rapid recombination screening to test gene essentiality demonstrates that pyrH is essential in Mycobacterium tuberculosis
- Dina Robertson, Paul Carroll, Tanya Parish
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?